X
Xiao-Dong Zhu
Researcher at Fudan University
Publications - 166
Citations - 5158
Xiao-Dong Zhu is an academic researcher from Fudan University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 27, co-authored 129 publications receiving 3734 citations. Previous affiliations of Xiao-Dong Zhu include Fudan University Shanghai Medical College & Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma
Xiao-Dong Zhu,Ju-Bo Zhang,Peng-Yuan Zhuang,Hongguang Zhu,Wei Zhang,Yuquan Xiong,Wei-Zhong Wu,Lu Wang,Zhao-You Tang,Hui-Chuan Sun +9 more
TL;DR: High peritumoral M-CSF and M Phi were associated with HCC progression, disease recurrence, and poor survival after hepatectomy, highlighting the importance of peritUMoral tissue in the recurrence and metastasis of HCC.
Journal ArticleDOI
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Ying Jiang,Aihua Sun,Yang Zhao,Yang Zhao,Wantao Ying,Hui-Chuan Sun,Xin-Rong Yang,Baocai Xing,Wei Sun,Liangliang Ren,Bo Hu,Li Chaoying,Li Zhang,Guangrong Qin,Menghuan Zhang,Ning Chen,Manli Zhang,Yin Huang,Zhou Jin'an,Yan Zhao,Mingwei Liu,Xiao-Dong Zhu,Yang Qiu,Yanjun Sun,Cheng Huang,Meng Yan,Mingchao Wang,Wei Liu,Fang Tian,Huali Xu,Jian Zhou,Zhenyu Wu,Tieliu Shi,Weimin Zhu,Jun Qin,Lu Xie,Jia Fan,Xiaohong Qian,Xiaohong Qian,Fuchu He +39 more
TL;DR: The proteomic stratification of early-stage hepatocellular carcinoma presented in this study provides insight into the tumour biology of this cancer, and suggests opportunities for personalized therapies that target it.
Journal ArticleDOI
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li,Shukui Qin,Jianming Xu,Weijian Guo,Jianping Xiong,Yuxian Bai,Guo-ping Sun,Yan Yang,Liwei Wang,Nong Xu,Ying Cheng,Zhehai Wang,Leizhen Zheng,M. Tao,Xiao-Dong Zhu,Dongmei Ji,Xin Liu,Hao Yu +17 more
TL;DR: Apatinib showed improved PFS and OS in heavily pretreated patients with mGC who had experienced treatment failure with two or more chemotherapy regimens, and this trial investigated the safety and efficacy of apatinib, an inhibitor of vascular endothelial growth factor receptor, as a treatment option.
Journal ArticleDOI
Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang,Xiao-Dong Zhu,Hui-Chuan Sun,Yuquan Xiong,Peng-Yuan Zhuang,Hua-Xiang Xu,Ling-Qun Kong,Lu Wang,Wei-Zhong Wu,Zhao-You Tang +9 more
TL;DR: Although sorafenib significantly inhibited tumor growth and lung metastasis, it induced a significant increase in peripheral recruitment and intratumoral infiltration of F4/80- and CD11b-positive cells, which was accompanied with elevation of colony-stimulating factor-1, stromal-derived factor 1α, and vascular endothelial growth factor in the tumor and peripheral blood, suggesting the role of macrophages in tumor progression under sorAFenib treatment.
Journal ArticleDOI
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Yuquan Xiong,Hui-Chuan Sun,Wei Zhang,Xiao-Dong Zhu,Peng-Yuan Zhuang,Ju-Bo Zhang,Lu Wang,Wei-Zhong Wu,Lun-Xiu Qin,Zhao-You Tang +9 more
TL;DR: TECs possessed enhanced angiogenic activity and resistance to chemotherapeutic drugs and an angiogenesis inhibitor, and may provide a better tool for studying tumorAngiogenesis and antiangiogenesis drugs in HCC.